FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Lupin Pharmaceuticals Ganirelix Acetate Injection Recall

Ganirelix Acetate Injection, 250 mcg/0

Lupin Pharmaceuticals Inc. · Naples, FL

Risk level
Class II
Reported by FDA
Dec 17, 2025
Recall ID
D-0220-2026
Check your lot numberHow we source this data

Summary

Lupin Pharmaceuticals recalled Ganirelix Acetate Injection starting Nov 13, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0220-2026 on Dec 17, 2025. Reason: Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity. Status: Ongoing.

Why it was recalled

Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.

Product description

Ganirelix Acetate Injection, 250 mcg/0.5mL, Single-dose Sterile Prefilled Syringe, 27 gauge by 1/2' needle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, United States, Manufactured by: Lupin Limited, Nagpur - 441108, INDIA, NDC 70748-274-01

Lot numbers, UPCs & expiration codes

Lot #: WB00006, Exp 12/31/2026

Where it was sold

FL, MA, MI & OH

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0220-2026
Classification
Class II
Status
Ongoing
Recall initiated
Nov 13, 2025
FDA report date
Dec 17, 2025
Quantity
32736 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Lupin Pharmaceuticals Inc.

Original FDA data

Every field from FDA enforcement report D-0220-2026, exactly as published.

Show all FDA fields
City
Naples
State
FL
Status
Ongoing
Country
United States
Event ID
97990
Address
5801 Pelican Bay Blvd
Address (line 2)
Suite 500
Code information
Lot #: WB00006, Exp 12/31/2026
Postal code
34108-2755
Report date
Dec 17, 2025
Product type
Drugs
Recall number
D-0220-2026
Classification
Class II
Recalling firm
Lupin Pharmaceuticals Inc.
Product quantity
32736 vials
Reason for recall
Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Ganirelix Acetate Injection, 250 mcg/0.5mL, Single-dose Sterile Prefilled Syringe, 27 gauge by 1/2' needle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, United States, Manufactured by: Lupin Limited, Nagpur - 441108, INDIA, NDC 70748-274-01
Distribution pattern
FL, MA, MI & OH
Recall initiation date
Nov 13, 2025
Initial firm notification
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Center classification date
Dec 8, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0220-2026, published Dec 17, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls